Bristol-Myers Squibb Co (LTS:0R1F)
$ 54.48 -1.095 (-1.97%) Market Cap: 109.81 Bil Enterprise Value: 153.11 Bil PE Ratio: 0 PB Ratio: 6.41 GF Score: 84/100

Bristol-Myers Squibb Company, MyoKardia, Inc. - M&A Call Transcript

Oct 05, 2020 / 12:00PM GMT
Release Date Price: $59.17 (-0.17%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Bristol-Myers Squibb acquisition of MyoKardia. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Tim Power, Vice President of Investor Relations. Please go ahead, sir.

Timothy Power
Bristol-Myers Squibb Company - VP & Head of IR

Great. Thanks, Sonia, and good morning, everyone. Thanks for joining us today for our call to discuss our acquisition of MyoKardia. Joining me today are Giovanni Caforio, our Board Chair and Chief Executive Officer; along with David Elkins, our Chief Financial Officer; Samit Hirawat, our Chief Medical Officer and Head of Global Drug Development; and Chris Boerner, our Chief Commercialization Officer. As a reminder, a slide presentation and press release regarding today's news are available on the Investor Relations section of Bristol-Myers Squibb website and we'll refer you to Slide 2 of today's presentation for our legal

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot